Sign In
Buy GNLX
$2.95
-0.0200 (-0.673%)
At Close: Jun 02, 2026
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:00am, Monday, 01'st Apr 2024
– Continued active enrollment of Olvi-Vec in our pivotal Phase 3 OnPrime/GOG-3076 trial in platinum resistant/refractory ovarian cancer with topline results anticipated in 2H 2025 – – Initiati
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
07:00am, Monday, 27'th Nov 2023
- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
05:50pm, Tuesday, 14'th Nov 2023
- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalent
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 14'th Sep 2023
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company'
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
04:01pm, Thursday, 07'th Sep 2023
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairma
Genelux: Biotech To Watch With Oncolytic Virus Immunotherapy In Late-Stage Testing
01:56pm, Wednesday, 30'th Aug 2023
Genelux has already initiated a phase 3 study known as OnPrime/GOG-3076, which is using the Olvi-Vec combination therapy to treat patients with platinum resistant/refractory ovarian cancer. In the pha
Genelux Corporation Announces New Chief Financial Officer
07:00am, Monday, 28'th Aug 2023
WESTLAKE VILLAGE, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Lourie S. Zak will join the company
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
07:00am, Monday, 14'th Aug 2023
- Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index - - Publication of VIRO-15 Phase 2 data in JAMA Oncology - - $51 Million raised after closing of two private
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023
04:00pm, Wednesday, 02'nd Aug 2023
WESTLAKE VILLAGE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and
Why Shares of Genelux Climbed This Week
10:54am, Friday, 28'th Jul 2023
Genelux recently announced management changes. The company's lead therapy is oncology treatment Olvi-Vec.
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
04:45pm, Thursday, 20'th Jul 2023
WESTLAKE VILLAGE, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as
Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer
04:12am, Tuesday, 11'th Jul 2023
Genelux, an immuno-oncology frontrunner, has secured over $65 million in financing and is conducting successful clinical trials for its primary candidate, Olvi-Vec, a cancer treatment that targets and
WESTLAKE VILLAGE, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the publication in Frontiers in Immunolog
IPO Round Up of First Half of 2023
12:17pm, Wednesday, 05'th Jul 2023
Normally, IPO activity gains momentum in the second quarter and peaks in June. This year was no exception.
Why Shares of Genelux Corporation Jumped This Week
05:19pm, Thursday, 01'st Jun 2023
Genelux focuses on hard-to-treat cancers. Its lead therapy is Olvi-Vec, which did well in a phase 2 trial to treat ovarian cancer.
